First-line chemotherapy with paclitaxel by three-hour infusion and carboplatin in advanced breast cancer (final report): A phase II study conducted by the Hellenic Cooperative Oncology Group

Annals of Oncology

Volumn 9, Issue 9, 1998, Pages 1031-1034

  Fountzilas, G ^a   Dimopoulos, A M ^b   Papadimitriou, C ^b   Kalogera Fountzila, A ^a   Aravantinos, G ^c   Bafaloukos, D ^d   Athanassiades, A ^a   Nicolaides, C ^d   Keramopoulos, A ^b   Pavlidis, N ^e   Kosmidis, P ^d   Skarlos, D ^c  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b ALEXANDRA HOSPITAL   (Greece)

^c AGII ANARGIRI CANCER HOSPITAL   (Greece)

^d METAXA CANCER HOSPITAL   (Greece)

^e UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Breast cancer; Carboplatin; Chemotherapy; Paclitaxel

Indexed keywords

ANTHRACYCLINE; CARBOPLATIN; CISPLATIN; MITOXANTRONE; PACLITAXEL;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG ACTIVITY; DRUG EFFICACY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MYALGIA; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT INDICATION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBOPLATIN; FEMALE; HUMANS; MIDDLE AGED; PACLITAXEL; TREATMENT OUTCOME;

EID: 7844246180     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008466928323     Document Type: Article

References (11)

1. Rowinsky EK, Donehower RC. Drug therapy: Paclitaxel (Taxol). N Engl J Med 1995; 332: 1004-14.
2. Gelmon KA. Biweekly paclitaxel in the treatment of patients with metastatic breast cancer. Semin Oncol 1995; 22 (Suppl 12): 117-22
3. O'Brien MER, Talbot DC, Smith IE. Carboplatin in the treatment of advanced breast cancer: A phase II study using a pharmacokinetically guided dose schedule. J Clin Oncol 1993; 11: 2112-7.
4. Fountzilas G, Athanassiadis A, Kalogera-Fountzila A et al. Paclitaxel by three-hour infusion and carboplatin in anthracycline-resistant advanced breast cancer. A phase II study conducted by the Hellenic Cooperative Oncology Group. Eur J Cancer 1997; 33: 1893-5.
5. Fountzilas G, Papadimitriou V, Bafaloukos D et al. Paclitaxel and carboplatin as first-line chemotherapy for advanced breast cancer. Oncology 1998; 12 (Suppl 1): 45-8.
6. Sparano JA, Neuberg D, Glick JH et al. Phase II trial of biweekly paclitaxel and cisplatin in advanced breast carcinoma: An Eastern Cooperative Oncology Group Study. J Clin Oncol 1997: 15: 1880-4.
7. Wasserheit C, Frazein A, Oratz R et al. Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer. An active regimen with limiting neurotoxicity. J Clin Oncol 1996; 14: 1993-9.
8. Ten Bokkel-Huinink WW, Van Warmerdam LJC. Helmerhorst TJ et al. Phase II study of the combination carboplatin and paclitaxel in patients with ovarian cancer. Ann Oncol 1997; 8: 351-4.
9. Langer CJ, Leighton JC, Comis RL et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: A phase H toxicity, response, and survival analysis. J Clin Oncol 1995; 13: 1860-70.
10. Kosmidis PA, Mylonakis N, Fountzilas G et al. Paclitaxel and carboplatin in inoperable non-small-cell cancer: A phase II study. Ann Oncol 1997; 8: 697-9.
11. Fountzilas G, Skarlos D. Athanassiadis A et al. Paclitaxel by three-hour infusion and carboplatin in advanced carcinoma of nasopharynx and other sites of the head and neck. A phase II study. Ann Oncol 1997; 8: 451-5.